#ExistInterpData>A post-immunization antibody concentration of 1.30 µg/mL or greater indicates adequate immune response. When comparing to pre-immunization concentrations that are 1.30 µg/mL or greater, a fourfold or greater increase in post-immunization concentration indicates adequate response; however, a high pre-immunization antibody concentration may preclude a fourfold increase.
Indication of immune system competence is demonstrated by an adequate immune response to at least 50 percent of the serotypes included in the vaccine challenge.
See Compliance Statement B: www.aruplab.com/CS
||Includes Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. (Conjugated Serotypes: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.).
This assay is designed to use both pre- and post-immunization specimens to assess immune responsiveness to pneumococcal vaccine. This test is not designed to determine protection to Streptococcus pneumoniae based on a single specimen.